Methemoglobinemia epidemiology and demographics

Jump to navigation Jump to search

Methemoglobinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Methemoglobinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Methemoglobinemia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Methemoglobinemia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Methemoglobinemia epidemiology and demographics

on Methemoglobinemia epidemiology and demographics

Methemoglobinemia epidemiology and demographics in the news

Blogs on Methemoglobinemia epidemiology and demographics

Directions to Hospitals Treating Methemoglobinemia

Risk calculators and risk factors for Methemoglobinemia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aksiniya Stevasarova, M.D.

Overview

The incidence of congenital methemoglobinemia in the United States is very low. There is no racial predilection to methemoglobinemia. The highest prevalence of G6PD deficiency is observed in the malaria-endemic regions: Sub-Saharan Afria, West Asia and Arabian Peninsula, as well as in people of Mediterranean descent.

Epidemiology and Demographics

The incidence of congenital methemoglobinemia in the United States is very low.

Age

  • Patients of all age groups may develop methemoglobinemia.
  • The acquired methemoglobinemia is a rare disease that tends to affect infants and people exposed to local anesthetics during medical procedures.
  • Infants, particularly those younger than 4 months are most susceptible to methemoglobinemia. This is due to the fact that the NADH methemoglobin reductase activity and concentration (the main protective enzyme against oxidative stress) is not fully mature in infants.

Gender

Developed Countries

  • There is no racial predilection to methemoglobinemia.
  • In developed countries, the incidence of acquired methemoglobinemia is higher in developing countries when people are exposed to local anesthetics during various medical procedures.
  • The majority of cytochrome b5 reductase deficiency cases are found among some Native American tribes like Navajo [1] and Athabaskan Alaskans, and the Yakutsk people in Siberia. [2]

Developing Countries

  • The highest prevalence of G6PD deficiency is observed in the malaria-endemic regions: Sub-Saharan Afria, West Asia and Arabian Peninsula, as well as in people of Mediterranean descent. [3] [4] [5]

References

  1. BALSAMO P, HARDY WR, SCOTT EM (1964). "HEREDITARY METHEMOGLOBINEMIA DUE TO DIAPHORASE DEFICIENCY IN NAVAJO INDIANS". J Pediatr. 65: 928–31. PMID 14244100.
  2. Burtseva TE, Ammosova TN, Protopopova NN, Yakovleva SY, Slobodchikova MP (2017). "Enzymopenic Congenital Methemoglobinemia in Children of the Republic of Sakha (Yakutia)". J Pediatr Hematol Oncol. 39 (1): 42–45. doi:10.1097/MPH.0000000000000705. PMID 27879543.
  3. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP; et al. (2013). "Spatial distribution of G6PD deficiency variants across malaria-endemic regions". Malar J. 12: 418. doi:10.1186/1475-2875-12-418. PMC 3835423. PMID 24228846.
  4. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI (2013). "G6PD deficiency: global distribution, genetic variants and primaquine therapy". Adv Parasitol. 81: 133–201. doi:10.1016/B978-0-12-407826-0.00004-7. PMID 23384623.
  5. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE; et al. (1991). "Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706". Int J Radiat Oncol Biol Phys. 21 (4): 935–9. PMID 1917622.

Template:WS Template:WH